CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
C

Venous thromboembolism

Hemostatic & ThromboticDisease / conditionriskpartially modifiable
20
evidence score
PREVENT status

Not a PREVENT input variable.

Causal support

trial evidence

Score components
lit volume: 4.8meta-analyses: 0trials: 15genetic: 0MR bonus:

References (2)

0 meta-analyses / systematic reviews

Clinical trials (31)

NCTTitleStatusTypeInterventions
NCT06440694Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis: A Randomized Controlled Pilot TrialRECRUITINGINTERVENTIONALColchicine 0.5 mg po, Placebo 0.5 mg po
NCT06845423Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk. An Open-label, Randomized, Controlled Trial Comparing Two Strategies With or Without Pharmacological ThromboprophylaxisRECRUITINGINTERVENTIONALLow molecular weight heparin
NCT06873321Incidence of Venous Thromboembolism After Lower Limb Revascularization in Patients Receiving Rivaroxaban 2.5 Mg Bid + Aspirin 100 Mg Versus Single Antiplatelet Treatment - a Randomized Clinical TrialRECRUITINGINTERVENTIONALrivaroxaban 2.5 mg bid + aspirin 100 mg, clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures
NCT03559114PROTEST Trial - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury, a Double-blind Randomized Controlled TrialRECRUITINGINTERVENTIONALDalteparin, Saline
NCT04662684Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE TrialCOMPLETEDINTERVENTIONALRivaroxaban 10 MG
NCT02503904Tumescent Antibiotic Delivery for Prevention of Surgical Site Infection: A Multicenter Open Label Randomized Clinical TrialUNKNOWNINTERVENTIONALConcomitant Tumescent Antibiotic Delivery & IV Delivery, Subcutaneous Tumescent Infiltration, cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)
NCT02379806Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) StudyCOMPLETEDINTERVENTIONALEnoxaparin, Placebo
NCT02331095A Pilot Study of Using Statins in Patients With Acute Venous Thromboembolism (VTE)TERMINATEDINTERVENTIONALAtorvastatin, Anticoagulation Therapy
NCT01401725Electronic Strategies to Enhance Venous Thromboprophylaxis in Hospitalized Medical PatientsCOMPLETEDINTERVENTIONALElectronic Order Entry System + CDSS, Electronic Order Entry System Only, Usual Care
NCT00895505Safety and Efficacy of a D-Dimer-Guided Strategy for Extension of Secondary Prophylaxis of Venous Thromboembolism - a Prospective and Randomized Management TrialUNKNOWNINTERVENTIONALPhenprocoumon, Warfarin-Natrium
NCT00457002A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.COMPLETEDINTERVENTIONALApixaban, Enoxaparin
NCT00437892The Effect of Statins on D-dimer Levels in Patients With a Previous Venous Thromboembolic EventTERMINATEDINTERVENTIONALatorvastatin, atorvastatin, diet
NCT00541320Dose Ranging Trial for the Evaluation of the Safety and Efficacy of GW813893 in the Prophylaxis of Venous Thromboembolism Post Total Knee Replacement Surgery.WITHDRAWNINTERVENTIONALGW813893
NCT00361894RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.COMPLETEDINTERVENTIONALRivaroxaban (BAY59-7939), Enoxaparin
NCT00329628RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip ReplacementCOMPLETEDINTERVENTIONALRivaroxaban (BAY59-7939), Enoxaparin
NCT00119457A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis With Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Following Hip Fracture SurgeryCOMPLETEDINTERVENTIONALTTP889
NCT00152971A Phase III, Randomized, Parallel-group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150 mg Day 2-completion, and 110 mg Day 1 Followed by 220 mg Day 2-completion) of Dabigatran Etexilate Administered Orally (Capsules), Compared to Enoxaparin 30 mg Twice a Day Subcutaneous for 12 - 15 Days in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement SurgeryCOMPLETEDINTERVENTIONALDabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion
NCT00222677Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.UNKNOWNINTERVENTIONALaspirin
NCT00398905Controlled, Double-Blind, Randomised, Dose-Ranging Study on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement- ODIXa-HIP2 Study BAY 59-7939COMPLETEDINTERVENTIONALRivaroxaban (Xarelto, BAY59-7939), Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban (Xarelto, BAY59-7939)
NCT00077805An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic StrokeCOMPLETEDINTERVENTIONALEnoxaparin sodium
NCT00655122Double-Blind, Placebo-Controlled, Pilot Study, In Medical Patients With Prophylaxis Of Venous Thromboembolism in Primary CareTERMINATEDINTERVENTIONALDalteparin sodium, Placebo
NCT00077753A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged ImmobilizationCOMPLETEDINTERVENTIONALenoxaparin sodium
NCT06353373Smart Technology Facilitated In-hospital Venous Thromboembolism Prophylaxis Based on Bundled Evidence-based Prevention Strategies: the SmaVTE-BEST StudyUNKNOWNOBSERVATIONALApplication of the modified DeVTEcare system
NCT05819125Comparison of the Risk of Venous Thromboembolism and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis With EnoxaparinTERMINATEDOBSERVATIONAL
NCT05396157Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study of Thrombosis / Bleeding Incidence and Prophylaxis TrendsACTIVE NOT RECRUITINGOBSERVATIONAL
NCT02742623COSIMO Cancer Associated Thrombosis - Patient Reported Outcomes With Rivaroxaban. A Non-interventional Study on Patients Changing to Xarelto® for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer.COMPLETEDOBSERVATIONALRivaroxaban (Xarelto, BAY 59-7939)
NCT02836457ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTECOMPLETEDOBSERVATIONAL
NCT02596230Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PECOMPLETEDOBSERVATIONAL
NCT01321788Venous Thromboembolism Prophylaxis Post Cesarean Section(PRO-CS-Trial)UNKNOWNOBSERVATIONALTINZAPARIN, PLACEBO
NCT00354796The Effect of Reduced Dose of Enoxaparin on the Laboratory and Clinical Outcomes of Treatment With EnoxaparinUNKNOWNOBSERVATIONAL
NCT00303407Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative CareTERMINATEDOBSERVATIONALnadroparin

Genetic associations (0)

None linked.